Estimating the probability of demonstrating vaccine efficacy in the declining Ebola epidemic: A Bayesian modelling approach

BMJ Open

Volumn 5, Issue 12, 2015, Pages

  Camacho, Anton ^a   Eggo, Rosalind M ^a   Funk, Sebastian ^a   Watson, Conall H ^a   Kucharski, Adam J ^a   Edmunds, W John ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; VACCINE;

ARTICLE; BAYES THEOREM; CONTROLLED STUDY; EBOLA HEMORRHAGIC FEVER; EPIDEMIC; FEASIBILITY STUDY; HUMAN; IMMUNITY; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; VACCINATION; BIOLOGICAL MODEL; HEMORRHAGIC FEVER, EBOLA; INCIDENCE;

BAYES THEOREM; EPIDEMICS; HEMORRHAGIC FEVER, EBOLA; HUMANS; INCIDENCE; MODELS, BIOLOGICAL; PROBABILITY; VACCINES;

EID: 84960397648     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-009346     Document Type: Article

References (14)

1. Agua-Agum J, Ariyarajah A, Aylward B, et al., WHO Ebola Response Team. West African Ebola epidemic after one year- slowing but not yet under control. N Engl J Med 2015;372:584-7.
2. Centre for the Mathematical Modelling of Infectious Diseases. Visualisation and projections of the Ebola outbreak in West Africa. London Sch. Hyg. Trop. Med. http://ntncmch.github.io/ebola/(accessed 7 Jun 2015).
3. Piszczek J, Partlow E. Stepped-wedge trial design to evaluate Ebola treatments. Lancet Infect Dis 2015;15:762-3.
4. Ebola ça suffit ring vaccination trial consortium. The ring vaccination trial: a novel cluster randomized controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola. BMJ 2015;351:h3740.
5. Kupferschmidt K. Scientists argue over access to remaining Ebola hotspots. Science. http://news.sciencemag.org/africa/2015/03/scientists-argue-over-access-remaining-ebola-hotspots? intcmp=collection-ebola
6. Bellan SE, Pulliam JR, Pearson CA, et al. Statistical power and validity of Ebola vaccine trials in Sierra Leone: a simulation study of trial design and analysis. Lancet Infect Dis 2015;15: 703-10.
7. World Health Organisation. Ebola Situation Reports. http://apps.who. int/ebola/ebola-situation-reports (accessed 7 Jun 2015).
8. Dureau J, Kalogeropoulos K, Baguelin M. Capturing the time-varying drivers of an epidemic using stochastic dynamical systems. Biostatistics 2013;14:541-55.
9. Camacho A, Kucharski A, Aki-Sawyerr Y, et al. Temporal changes in Ebola transmission in Sierra Leone and implications for control requirements: a Real-time Modelling Study. PLoS Curr 2015;7.
10. Andrieu C, Doucet A, Holenstein R. Particle Markov chain Monte Carlo methods. J Roy Stat Soc B 2010;72:269-342.
11. Dureau J, Ballesteros S, Bogich T. SSM: Inference for time series analysis with State Space Models. arXiv.org. 2013. http://arxiv.org/abs/1307.5626
12. Halloran ME, Longini IM Jr, Struchiner CJ. Design and analysis of vaccine studies. New York, NY: Springer New York, 2010.
13. Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 2015;386:857-66.
14. Scherer R. R package PropCIs version 0.2-5. riskscoreci score confidence interval for the rela. 2014. http://cran.r-project.org/web/packages/PropCIs/index.html